Predictor of treatment response in schizophrenia?

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1280, 2001-01, pp. : 18-18

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Bifeprunox: beneficial in schizophrenia?

Inpharma, Vol. 1, Iss. 1570, 2007-01 ,pp. : 9-10

Adis International

Access to resources Recommend Favorite

Atypical antipsychotics cause diabetes mellitus in schizophrenia?

Inpharma, Vol. 1, Iss. 1289, 2001-01 ,pp. : 20-20

Adis International

Access to resources Recommend Favorite

Does Olanzapine Warrant Clinical Pharmacokinetic Monitoring in Schizophrenia?

By Schwenger Erin Dumontet Jane Ensom Mary H.H.

Clinical Pharmacokinetics, Vol. 50, Iss. 7, 2011-07 ,pp. : 415-428

Adis International

Access to resources Recommend Favorite

Do QOL scores reflect therapy in schizophrenia?

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 310, 2001-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Do Acetylcholinesterase Inhibitors Have a Role in Improving Cognitive Impairment in Patients with Schizophrenia?

By Alessandro Lenzi Daniela Tuscano

International Journal of Pharmaceutical Medicine, Vol. 18, Iss. 3, 2004-01 ,pp. : 139-148

Adis International

Access to resources Recommend Favorite